News Quantified

APRE – aprea therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update [Yahoo! Finance]

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

Form SCHEDULE 13G Aprea Therapeutics, Inc. Filed by: LYTTON LAURENCE W

Form 10-Q Aprea Therapeutics, Inc. For: Sep 30

Form 8-K Aprea Therapeutics, Inc. For: Nov 12

Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: Sio Capital Management, LLC

Form 8-K Aprea Therapeutics, Inc. For: Oct 24

Top News Gainers

10/2 Form 3 Aprea Therapeutics, Inc. For: Oct 02 Filed by: Coiante Scott M 32.6%

11/14 Aprea Therapeutics (NASDAQ: APRE) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 10.6%

12/12 Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) An 9.3%

3/27 Aprea Therapeutics (NASDAQ: APRE) had its "hold" rating re-affirmed by analysts at Morgan Stanley. They now have a $36.00 price target on the stock. 9.1%

4/3 Form 8-K Aprea Therapeutics, Inc. For: Apr 03 6.5%

10/7 U.S. IPO Weekly Recap: Oncology Biotech Aprea Therapeutics Finishes On Top In 4-IPO Week [Seeking Alpha] 6.2%

10/17 Form SC 13D Aprea Therapeutics, Inc. Filed by: 5AM Ventures IV, L.P. 4.5%

1/13 Form 8-K Aprea Therapeutics, Inc. For: Jan 13 3.6%

10/9 Form 4 Aprea Therapeutics, Inc. For: Oct 07 Filed by: Schwab Andrew J. 2.1%

11/18 Form S-8 Aprea Therapeutics, Inc. 2.0%

Top News Decliners

3/26 Q4/2019 12/31/2019 EPS -0.640 ZacksConsensus -0.390 ActVsEst (0.250) - Miss -11.5%

10/4 Form 424B4 Aprea Therapeutics, Inc. -8.7%

12/9 Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual -7.7%

10/7 Form 4 Aprea Therapeutics, Inc. For: Oct 07 Filed by: Seizinger Bernd R. -7.6%

4/29 Form DEFA14A Aprea Therapeutics, Inc. -5.6%

2/14 Form SC 13G Aprea Therapeutics, Inc. Filed by: KDev Investments AB -4.6%

2/13 Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial -4.1%

10/28 Aprea Therapeutics (NASDAQ: APRE) is now covered by analysts at JPMorgan Chase & Co.. They set a "neutral" rating on the stock. -2.8%

11/12 Form SC 13G Aprea Therapeutics, Inc. Filed by: FMR LLC -2.4%

1/9 Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 -2.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day